Physician profile
Michael D Woolery
NPI 1881699114
$1,757.91
in general payments reported to CMS, 2019-2025
14 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $59.40 · 2021: $158 · 2022: $271 · 2023: $452 · 2024: $402 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,173.33 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $117.06 | 2019-2020 | |
| Edwards Lifesciences Corporation | $103.55 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $75.99 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $57.32 | 2023-2024 | Vaxneuvance, Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $41.96 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.32 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $36.30 | 2020-2021 | |
| Pfizer INC. | $30.06 | 2020 | |
| Lilly USA, LLC | $27.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.23 | 2025 | Airsupra |
| Sumitomo Pharma America, INC. | $14.83 | 2025 | Gemtesa |
| Dexcom, INC. | $13.67 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Woolery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.